OPVEE
Asset
- Stage
- Approved
- Modality
- Not known
- Target
- Not known
- 1
- Indication
- 0
- Trials
- 1
- Developer
Approved by the FDA on May 22, 2023 (NDA217470). FDA
Indications
1No named disease
Approved, FDA, May 22, 2023
In the full profile
- Owner and partners1
Every asset’s record: target, stage, trials and the evidence behind it.